No. Neuralink announced on September 17, 2024, that the FDA had granted its Blindsight implant Breakthrough Device Designation for people with vision impairment. That designation is intended to support development and review; it is not FDA marketing authorization, proof that Blindsight works, or evidence that it is available to patients.
What Neuralink announced about Blindsight
Neuralink said on September 17, 2024: “We have received Breakthrough Device Designation from the FDA for Blindsight, for individuals with vision impairment.” This is the company’s public report of the designation. The FDA generally cannot disclose whether a sponsor requested or received designation before marketing authorization unless the sponsor chooses to make that information public. Neuralink’s announcement is that public disclosure.
What Breakthrough Device Designation means
The FDA’s voluntary Breakthrough Devices Program is intended to help eligible devices move through development, assessment, and review in a way that may provide more timely patient access. A sponsor may request designation before submitting a marketing application. If the FDA grants it, the sponsor may have opportunities to interact with FDA experts and receive prioritized review of future submissions. Designation does not guarantee approval or a faster path to market.
The FDA says: “Breakthrough Devices must meet the FDA’s rigorous standards for device safety and effectiveness in order to be authorized for marketing.” The agency describes the program and its limits on its Breakthrough Devices Program page.
#1 Best Overall
Designation and marketing authorization are different milestones
| Milestone | Purpose and timing | What it establishes |
|---|---|---|
| Breakthrough Device Designation | A voluntary program status that can support development and review; a sponsor may request it before submitting a marketing application. | Eligibility for program support, including opportunities for FDA interaction and prioritized review of future submissions. It does not establish that the device is safe or effective, or permit marketing. |
| Marketing authorization | A separate FDA decision through an applicable pathway, such as PMA, 510(k), or De Novo. | Permission to market the device through that pathway after the relevant safety and effectiveness standards are met. |
So the designation is not FDA approval, clearance, or a finding that Blindsight has restored vision in patients. Whether and when the device could be marketed depends on a separate regulatory decision.
What the public information does not establish about Blindsight
Neuralink’s announcement and the FDA program page do not establish Blindsight’s detailed technical design, whether a Blindsight-specific clinical trial has begun, patient outcomes, safety findings, an expected launch date, or commercial availability. Neuralink’s separate PRIME/N1 trial should not be treated as evidence about Blindsight.
Neuralink’s June 2, 2025 funding announcement refers broadly to its “vision” restoration program receiving designation, but it does not provide Blindsight trial results or announce marketing authorization. The funding announcement therefore does not change what the designation itself means.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.FDA program totals are not Blindsight status updates
As of June 30, 2026, the FDA reported 1,320 Breakthrough Device designations and 210 matching marketing authorizations across the program. The FDA defines the latter as devices authorized for an indication consistent with their breakthrough designation. These are program-wide totals; they do not indicate that Blindsight has received authorization or predict its outcome.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
